GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Institutional Ownership

Patrys (ASX:PAB) Institutional Ownership : 0.09% (As of Dec. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Patrys Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Patrys's institutional ownership is 0.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Patrys's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Patrys's Float Percentage Of Total Shares Outstanding is 0.00%.


Patrys Institutional Ownership Historical Data

The historical data trend for Patrys's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Patrys Institutional Ownership Chart

Patrys Historical Data

The historical data trend for Patrys can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09

Patrys Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Patrys Business Description

Industry
Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

Patrys Headlines